Clinical Trials About "Consultant suspended nine months risking patient safety" RSS

22:57 EDT 16th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Consultant suspended nine months risking patient safety" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Consultant suspended nine months risking patient safety" on BioPortfolio

We have published hundreds of Consultant suspended nine months risking patient safety news stories on BioPortfolio along with dozens of Consultant suspended nine months risking patient safety Clinical Trials and PubMed Articles about Consultant suspended nine months risking patient safety for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Consultant suspended nine months risking patient safety Companies in our database. You can also find out about relevant Consultant suspended nine months risking patient safety Drugs and Medications on this site too.

Showing "Consultant suspended nine months risking patient safety" Clinical Trials 1–25 of 24,000+


Evaluation of Diabetes Self-Management Consultant Care

The purpose of this study is to find out if Self-Management Consultant (SMC) intervention will be more effective than usual care in improving blood glucose control and diabetes-related quality of life for adults with type 2 diabetes.

Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT

This is a randomized, controlled, single-center, single-blind, 2x2 factorial design trial of routine provider, primary care-based interventions to increase breastfeeding intensity up to 6 months in low-income multiethnic women, with stratification for maternal country of birth. The Best Infant Nutrition for Good Outcomes (BINGO) trial will randomize women into one of four treatment groups: (a) Prenatal Care Provider (PNC); (b) Lactation Consultant (LC); (c) PNC + LC, or; (d) Co...

Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance

INDICATION: Patients with chronic hepatitis C, genotype 1 and non-responders to standard treatment for hepatitis C. OBJECTIVES: 1. ascertain the rate of sustained response in patients with hepatitis C, genotype 1 with peginterferon + ribavirin resistance. 2. To know the response rate in 12 weeks 3. Describe the tolerance and safety of thalidomide in combination with peginterferon and ribavirin. DESIGN OF TEST Pilot Study: The...

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.

The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy

Liver tumors are hard to treat with radiation because the liver moves every time you breathe. The purpose of this study is to test a new and possibly more accurate way of treating liver tumors. When a person is asleep under anesthesia, it is safe to stop breathing motion for a while. The liver will stop moving and radiation can be given to a liver tumor. The study is being done to see if radiation can be given to liver tumors safely and accurately in this way.

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

Dolutegravir is an HIV-1 integrase inhibitor which is marketed as a single tablet (Tivicay®) and in a fixed dose combination tablet with abacavir and lamivudine (Triumeq®, referred to as TRI). For patients with swallowing difficulties, administration of whole tablets can be problematic and tablets are cut or crushed to ease administration. Currently there is no information about crushing TRI tablets. Therefore this study will be conducted to investigate whether crushed and s...

Suspended Overlength Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture

Endoscopic insertion of plastic or metal stents in introhepatic bile duct under endoscopic retrograde cholangiopancreatography is a well established treatment of malignant or benign biliary obstruction.Biliary stents are widely used to relieve symptoms of biliary stricture.Now, the mainly used biliary stents include plastic and metal stents. The main limitation of long time plastic stents is stents occlusion. Biliary plastic stents are changed every 2 to 3 months due to an expe...

Independent Prescribing Optometrists in Acute Ophthalmic Services

The UK government's Crown report titled 'Review of prescribing, supply & administration of medicines' enabled optometrists to train for the qualification of independent prescribing (IP). The UK introduced IP for optometrists in 2009. The proposed research focuses on the role of IP optometrist in the acute ophthalmic services of Manchester Royal Eye Hospital (MREH). The study will compare IP optometrists to consultant ophthalmologists in the ability to diagnose, manage and presc...

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or control group with the ratio of 4:1 and receiving the test or control drug 1 time or 2 times.

3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

To determine whether 3 months' anticoagulation is as good as or better than 6 months' for the treatment of DVT/PE

Pilot Study to Assess the Feasibility and Initial Efficacy of Therapist-as-consultant, Game-based CI Therapy

Pilot study to assess the feasibility and initial efficacy of therapist-as-consultant, game-based CI therapy. Pre/post study design. Participant received a target of 30 hours game-based motor intervention, 100 hours constraint of the less affected upper extremity, and 5 hours therapist consultation (including completion of a behavioral contract at the first study visit). Duration of intervention was 10 consecutive weekdays, with pre-treatment and post-treatment testing performe...

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and as a booster dose at 18 months of age in Russian healthy children according to the Russian immunisation schedule

Compare Chemotherapy of XELOX for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.

Our study aims to compare the efficacy and safety of capecitabine and oxaliplatin for 4 months versus 6 months as adjuvant chemotherapy after D2 Gastrectomy in patients with gastric cancer. Hypothesis: For gastric patients after D2 Gastrectomy, capecitabine and oxaliplatin for 4 months shows noninferiority to capecitabine and oxaliplatin for 6 months in disease free survival(DFS) and safety.

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-Priming With GSK Vaccine 792014

The purpose of the study is to characterize the immunogenicity & safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged Between >= 6 Months to < 18 Years

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in patients 6 months to less than 6 years of age with severe atopic dermatitis (AD).

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.

A Safety and Feasibility Study of Re-treating Patients With Severe Emphysema With the RePneu LVRC System.

Rationale: The combined data from 3 studies outside the Unites States investigating the Lung Volume Reduction Coil system (RePneu LVRC) showed statistically significant improvements in pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months post treatment. 24 months post treatment the improved pulmonary function and exercise capacity are slightly decreasing. Retreating the patient with the LVR coil system in other parts of the lung could ...

A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children.

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants 3 Months to <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants 3 months to

A Phase 2 Study of AZD6244 in Hepatocellular Carcinoma

AZD6244 will be administered at a dose of 100 mg twice daily approximately 12 hours apart, in a mix and drink formulation for the first 6 patients. Patients in the safety cohort will be counted toward the efficacy endpoints. Enrollment of patients with moderate liver dysfunction will be held when the 6th patient begins therapy (if patients are enrolled simultaneously at several sites such that the number exceeds 6, all will be included in safety cohort analysis). Upon completi...

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

The purpose of this study is to assess the bioavailability, safety, tolerability and pharmacokinetics of two tablet formulations as compared to the capsule formulation suspended in liquid.

Provider Approaches to Improved Rates of Infant Nutrition and Growth Study

We will conduct a randomized, controlled trial of routine, pre-natal care practice-site based pre- and post-natal breastfeeding promotion interventions in low-income minority women, with stratification for maternal country of origin. Our primary outcome measure is breastfeeding duration and extent, i.e. "intensity." Our secondary outcomes measures are: a) infant weight, and b) participant/ provider experiences of the intervention. The Provider Approaches to Improved Rates of I...

A Trial to Evaluate the Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid, Administered Twice, at Three Dosage Levels and Two Dosing Intervals

This phase 2 study will evaluate the safety, immunogenicity and optimal timing of two injections at three dose levels of the tgAAC09 vaccine in healthy volunteers. Study volunteers will receive two intramuscular injections of tgAAC09 or placebo at Months 0 and 6 (groups A, C, E and G) or at Months 0 and 12 (groups B, D and F) and be followed for a total of 18 months following the first injection with the exception of group G in which volunteers will be followed for 12 months af...

Relative Bioavailability Study

To investigate relative bioavailability of crushed tablets suspended in apple sauce or water

More From BioPortfolio on "Consultant suspended nine months risking patient safety"

Quick Search